Source-grounded facts extracted from Arcturus Therapeutics Holdings Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcturus Therapeutics Holdings Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-05 meeting.
“Proposal No. 3 For Against Abstain Broker Non-Votes Approval of the ratification of the appointment of Deloitte as the Company's independent registered public accounting firm”
Arcturus Therapeutics Holdings Inc. shareholders approved Approval, on a non-binding advisory basis, the resolution approving named executive officer compensation at the 2026-06-05 meeting.
“Proposal No. 2 For Against Abstain Broker Non-Votes Approval, on a non-binding advisory basis, the resolution approving named executive officer compensation”
Arcturus Therapeutics Holdings Inc. shareholders approved Election of eight directors at the 2026-06-05 meeting.
“Proposal No. 1 For Withhold Broker Non-Votes Approval of the election of the following individuals as directors of the Company”
Arcturus Therapeutics Holdings Inc. reported financial results for the quarter ended March 31, 2026.
“today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.”
Dennis Mulroy was appointed as Chief Financial Officer at Arcturus Therapeutics Holdings Inc..
“Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.”
Moncef Slaoui was appointed as Member of the Board of Directors at Arcturus Therapeutics Holdings Inc..
“On June 19, 2024, Dr. Moncef Slaoui, Ph.D., agreed to serve as a member of the Board of Directors”
Arcturus Therapeutics Holdings Inc. reported the three months ended March 31, 2024 results: revenue $38.0 million.
“For the three months ended March 31, 2024, revenues were $38.0 million compared with $80.3 million for the three months ended March 31, 2023.”
Arcturus Therapeutics Holdings Inc. engaged Deloitte & Touche LLP as its auditor.
“Effective April 5, 2024, the Audit Committee authorized the appointment of Deloitte & Touche LLP (" Deloitte ") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2024, and Deloitte was appointed as the Company's independent registered public accounting firm.”
Arcturus Therapeutics Holdings Inc. dismissed Ernst & Young LLP as its auditor.
“the audit committee of the board of directors (the " Audit Committee ") of Arcturus Therapeutics Holdings Inc.'s (the " Company " or " Arcturus ") authorized the dismissal of Ernst & Young LLP (" EY ") as the Company's independent registered public accounting firm, and EY was dismissed as the Company's independent registered public accounting firm as of such date.”
Arcturus Therapeutics Holdings Inc. reported fiscal fourth quarter 2023 results: revenue $25.0, net income $11.7 million, EPS $0.44 per share.
“the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.”
Arcturus Therapeutics Holdings Inc. reported fiscal year ended December 31, 2023 results: revenue $157.7 million, net income $29.7 million, EPS $1.12 per share.
“the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.”
Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2023 results: revenue $169.9 million.
“For the year ended December 31, 2023, we reported revenue of $169.9 million compared with $206.0 million for the year ended December 31, 2022.”
Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2023 results: revenue $34.0 million.
“For the three months ended December 31, 2023, revenue recognized was $34.0 million compared with $160.3 million for the three months ended December 31, 2022.”
Joseph Roberts changed role as Controller at Arcturus Therapeutics Holdings Inc..
“Joseph Roberts, formerly the Company’s Assistant Controller, has been promoted to Controller of the Company.”
Keith C. Kummerfeld resigned as Senior Vice President of Finance and Corporate Controller at Arcturus Therapeutics Holdings Inc..
“Keith C. Kummerfeld, Senior Vice President of Finance and Corporate Controller of Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”), informed the Company that he will resign from his position with the Company, effective March 15, 2024, to pursue another opportunity.”
Arcturus Therapeutics Holdings Inc. reported financial results for third quarter ended Sept. 30, 2023.
“On November 14, 2023, Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update (the “Press Release”).”
Arcturus Therapeutics Holdings Inc. amended the "Amendment" with Cystic Fibrosis Foundation valued at up to $9 million (effective 2023-09-25).
“On September 25, 2023, Arcturus Therapeutics, Inc. (" Arcturus "), a subsidiary of Arcturus Therapeutics Holdings Inc. (the " Company "), entered into an amendment (the " Amendment ") to its Development Program Letter Agreement of May 16, 2017”
Arcturus Therapeutics Holdings Inc. entered into CSL Collaboration Agreement with Seqirus, Inc., a part of CSL Seqirus (effective 2022-12-08).
“the Company entered into the CSL Collaboration Agreement with CSL Seqirus for the global exclusive rights to research, develop, manufacture and commercialize Arcturus’ self-amplifying mRNA vaccines against COVID-19, influenza and three other respiratory infectious diseases with nonexclusive rights to pandemic pathogens”
Arcturus Therapeutics Holdings Inc. reported the second quarter and six months ended June 30, 2023 results: revenue $10.5 million.
“For the three months ended June 30, 2023, we reported revenue of $10.5 million compared with $27.1 million for the three months ended June 30, 2022.”
Arcturus Therapeutics Holdings Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“Approval of the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023, as provided in Proposal Number 3 of the Proxy Statement: 18,955,484 22,224 9,294 N/A”
Arcturus Therapeutics Holdings Inc. shareholders approved To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation (say-on-pay) at the 2023-06-14 meeting.
“Approval, on a non-binding advisory basis, the resolution approving named executive officer compensation , referred to as "say-on-pay," as provided in Proposal Number 2 of the Proxy Statement: 11,959,501 4,562,055 15,403 2,450,043”
Arcturus Therapeutics Holdings Inc. shareholders approved To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz and Dr. John H. Markels to the Board of Directors at the 2023-06-14 meeting.
“(1) To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz and Dr. John H. Markels to the Board of Directors”
Arcturus Therapeutics Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $80.3 million.
“Total revenue for the three months ended March 31, 2023, was $80.3 million”
Arcturus Therapeutics Holdings Inc. incurred revolving credit of $50 million revolving credit line with Wells Fargo Bank, National Association at 1.00% above either the Daily Simple SOFR or Term SOFR maturing two years.
“On April 21, 2023, Arcturus Therapeutics, Inc. (“Borrower”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc. (the “Company”, and together with Borrower, “Arcturus”), entered into a credit agreement (the “Credit Agreement”) Wells Fargo Bank, National Association (“Wells Fargo”) whereby Wells Fargo will make a $50 million revolving credit line available to Arcturus (the “Loan”)”
Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2022 results: revenue $206.0 million, net income approximately $9.3 million, EPS $0.35 per diluted share.
“Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31, 2022, were $193.8 million compared with $215.2 million for the year ended December 31, 2021. Research and development expenses : Research and development expenses for the three months ended December 31, 2022, were $27.0 million com”
Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2022 results: revenue $160.3 million, net income approximately $117.3 million, EPS $4.33 per diluted share.
“For the three months ended December 31, 2022, the Company reported revenue of $160.3 million compared with $5.8 million for the three months ended December 31, 2021, and $13.4 million for the three months ended September 30, 2022. Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31,”
Arcturus Therapeutics Holdings Inc. terminated Western Alliance Agreement with Western Alliance Bank valued at approximately $7.36 million (effective 2023-03-14).
“On March 14, 2023, the Loan and Security Agreement, dated as of October 12, 2018 (as amended and supplemented, the “Western Alliance Agreement”) by and between Arcturus Therapeutics, Inc. (“Arcturus Therapeutics”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings, Inc. (the “Company” and together with Arcturus Therapeutics, “Arcturus”), and Western Alliance Bank, an Arizona corporation (“Western Alliance”), was terminated (the “Termination”) upon the receipt by Western Alliance of a payoff amount of approximately $7.36 million from Arcturus.”
John Markels was appointed as Director at Arcturus Therapeutics Holdings Inc..
“On December 8, 2022, Dr. John Markels agreed to serve as a member of the Board of Directors of Arcturus Therapeutics Holdings Inc.”
Arcturus Therapeutics Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $13.4 million, net income net loss of approximately $35.3 million, or ($1.33) per basic and diluted share.
“from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended September 30, 2022, the Company reported revenue of $13.4 million compared with $2.4 million for the three months ended September 30, 2021, and $27.1 million for the three months ended June 30, 2022. Revenue increased by $10.9 million during”
Arcturus Therapeutics Holdings Inc. terminated Framework Drug Substance Supply Agreement with Vinbiocare Research and Manufacture Joint Stock Company valued at terminated by mutual agreement; no penalties (effective 2022-10-31).
“and (2) Framework Drug Substance Supply Agreement (the “Supply Agreement”), signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company, attached as Exhibit 10.33 to Arcturus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 10, 2021 (File No. 001-38942).”
Arcturus Therapeutics Holdings Inc. terminated Technology License and Technical Support Agreement with Vinbiocare Research and Manufacture Joint Stock Company valued at terminated by mutual agreement; no penalties (effective 2022-10-31).
“On October 31, 2022, Arcturus and Vinbiocare executed a letter agreement terminating the following agreements, effective October 31, 2022: (1) Technology License and Technical Support Agreement (the “License Agreement”), signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company, attached as Exhibit 10.32 to Arcturus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 10, 2021 (File No. 001-38942);”
Arcturus Therapeutics Holdings Inc. terminated Research Collaboration and License Agreement with Janssen Pharmaceuticals, Inc. valued at terminated in its entirety for convenience; effective 60 days after notice; no penalties (effective 2022-10-31).
“On October 31, 2022, Arcturus received notice of termination from Janssen Pharmaceuticals, Inc. of the Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Janssen Pharmaceuticals, Inc., dated October 18, 2017 (the “Janssen Agreement”).”
Arcturus Therapeutics Holdings Inc. entered into Study Support Agreement with Vinbiocare Biotechnology Joint Stock Company valued at limited payments through Q1 2025; single digit percentage of net sales of ARCT-154 up to a capped am (effective 2022-10-31).
“On October 31, 2022, Arcturus Therapeutics, Inc. (“Arcturus”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., entered into a Study Support Agreement (the “Support Agreement”) with Vinbiocare Biotechnology Joint Stock Company (“Vinbiocare”), a company established under the laws of Vietnam.”
Arcturus Therapeutics Holdings Inc. entered into Collaboration and License Agreement with CSL Seqirus, Inc. valued at Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial (effective 2022-11-01).
“On November 1, 2022, Arcturus Therapeutics Holdings Inc. ("Arcturus") entered into a Collaboration and License Agreement (the "Collaboration Agreement") with CSL Seqirus, Inc., a part of CSL Limited ("CSL Seqirus"), one of the world’s leading influenza vaccine providers, for the research, development, manufacture and global commercialization of self-amplifying mRNA vaccines.”
Kelly Lindert was appointed as Chief Development Officer, Vaccines at Arcturus Therapeutics Holdings Inc..
“Dr. Kelly Lindert, the Company’s Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the Company.”
Steve Hughes departed as Chief Medical Officer at Arcturus Therapeutics Holdings Inc..
“Effective February 14, 2022, Dr. Steve Hughes will step down from his position as Chief Medical Officer of Arcturus Therapeutics Holdings Inc.”
Jing Marantz was appointed as director at Arcturus Therapeutics Holdings Inc..
“the Board subsequently appointed Dr. Jing Marantz to serve as a director of the Company, effective as of December 7, 2021”
Karah Parschauer resigned as Director at Arcturus Therapeutics Holdings Inc..
“On August 25, 2021, Karah Parschauer notified the board of directors (the “Board”) of Arcturus Therapeutics Holdings Inc. (the “Company”) of her resignation from the Board and any associated committees of the Board, effective August 25, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.